<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00954252</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-0814-PR-0008</org_study_id>
    <nct_id>NCT00954252</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects</brief_title>
  <acronym>CT01</acronym>
  <official_title>Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CERESPIR</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CERESPIR</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of single oral doses of
      CHF 5074 in young healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint of the study is to determine the maximum tolerated dose (MTD) of CHF5074
      after single oral administration to young healthy male volunteers.

      The secondary objective of this study is to evaluate the pharmacokinetics of CHF5074 after
      single oral administration to young healthy male volunteers. The secondary endpoint of this
      study is to verify if CHF5074 plasma levels (Cmax and AUC0-t) increase proportionally with
      the dose (dose-linearity).

      The exploratory objective of this study is to evaluate the pharmacodynamics of CHF5074 after
      single oral administration to young healthy male volunteers. The respective exploratory
      endpoint is to assess the relationship between individual maximum CHF5074 plasma
      concentrations and corresponding A-beta42 plasma concentrations corrected for baseline
      A-beta42 levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>from Screening through Day +3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose linearity of CHF5074 plasma levels (Cmax and AUC0-t)</measure>
    <time_frame>Day -1 through Day +3</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Test Article</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5074</intervention_name>
    <description>1x, oral capsule, single dose</description>
    <arm_group_label>Test Article</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo, oral capsule, single dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5074</intervention_name>
    <description>2x, oral capsule, single dose</description>
    <arm_group_label>Test Article</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5074</intervention_name>
    <description>4x, oral capsule, single dose</description>
    <arm_group_label>Test Article</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5074</intervention_name>
    <description>8x, oral capsule, single dose</description>
    <arm_group_label>Test Article</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5074</intervention_name>
    <description>16x, oral capsule, single dose</description>
    <arm_group_label>Test Article</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5074</intervention_name>
    <description>24x, oral capsule, single dose</description>
    <arm_group_label>Test Article</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject's written informed consent is obtained prior to any study-related procedures.

          -  Subject is nonsmoking male between 18 and 45 years of age, inclusive.

          -  Subject has a body mass index between 18 and 30 kg/m2, inclusive.

          -  Subject is judged, by the investigator, to be in good health on the basis of medical
             history, complete physical examination including vital signs, 12-lead
             electrocardiogram (ECG) and standard laboratory tests including complete hematology,
             blood chemistry (glucose, creatinine, blood urea nitrogen, alanine aminotransferase,
             aspartate aminotransferase, albumin, alkaline phosphatase, sodium, potassium), thyroid
             function, urinalysis (glucose, hemoglobin, blood, proteins, pH) and fecal occult
             blood.

          -  Subject understands the procedures and agrees to participate in the study program.

        Exclusion Criteria:

          -  Subject is mentally or legally incapacitated.

          -  Subject has a history of any illness that, in the opinion of the investigator and
             according to the protocol, might confound the results of the study or pose additional
             risk in administering CHF5074 to the subject.

          -  Subject has a medical history (within the last 10 years) of major cardiovascular,
             hepatic or renal disease.

          -  Subject has liver function test abnormalities with elevated AST or ALT greater than or
             equal to 2 times upper limit of normal and/or elevated bilirubin greater than or equal
             to 2 times upper limit of normal.

          -  Subject has renal function test abnormalities, including serum creatinine greater than
             1.8 g/dL.

          -  Subject has abnormal fasting serum concentrations of TSH, T3 or T4.

          -  Subject has a positive result for fecal occult blood testing performed at screening.

          -  Subject has clinically significant abnormalities on physical examination, ECG or
             laboratory tests carried out at screening.

          -  Subject has a history of a psychiatric disorder.

          -  Subject has significant allergic conditions that require medical treatment or has
             known hypersensitivity to medications that could be activated by CHF5074 treatment.

          -  Subject is positive on testing for hepatitis B surface antigen, hepatitis C antibody
             or HIV 1 or 2 antibodies.

          -  Subject has donated blood within the 1 month prior to screening.

          -  Subject has a history of alcohol or drug abuse in the past 12 months.

          -  Subject used any psychoactive, recreational or prescription drug within the 4 weeks
             prior to study drug administration.

          -  Subject has used ibuprofen, sulindac sulfide, indomethacin, flurbiprofen within 2
             weeks prior to study drug administration.

          -  Subject has used any other over-the-counter drug within 1 week prior to study drug
             administration Occasional treatment with acetaminophen or aspirin is permitted but
             must be reported to the investigator. Vitamins are permitted.

          -  Subject is positive on urine drug screening for drugs of abuse (cannabinoids, cocaine,
             opiates, amphetamines, barbiturates, benzodiazepines).

          -  Subject has evidence of alcohol on screening blood work and breathalyzer test.

          -  Subject does not agree to use a medically acceptable contraceptive (abstain from
             sexual intercourse, or use a condom with spermicide) for 7 days after study drug
             administration, or has not had a vasectomy at least 6 months prior to study
             participation.

          -  Subject is unlikely to comply with the study protocol or unable to understand the
             nature and scope of the study or the possible benefits or unwanted effects of the
             study treatments.

          -  Subject has participated in another investigational study within 30 days prior to
             screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel S Ross, MD, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iberica Clinical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Iberica Clinical Research Center</name>
      <address>
        <city>Eatontown, NJ 07724</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006 Mar 16;440(7082):352-7.</citation>
    <PMID>16541076</PMID>
  </reference>
  <reference>
    <citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008 Aug;14(8):837-42. doi: 10.1038/nm1782. Epub 2008 Jun 22.</citation>
    <PMID>18568035</PMID>
  </reference>
  <reference>
    <citation>Olson RE, Albright CF. Recent progress in the medicinal chemistry of gamma-secretase inhibitors. Curr Top Med Chem. 2008;8(1):17-33. Review.</citation>
    <PMID>18220929</PMID>
  </reference>
  <reference>
    <citation>Lleó A. Activity of gamma-secretase on substrates other than APP. Curr Top Med Chem. 2008;8(1):9-16. Review.</citation>
    <PMID>18220928</PMID>
  </reference>
  <reference>
    <citation>Lewis HD, Pérez Revuelta BI, Nadin A, Neduvelil JG, Harrison T, Pollack SJ, Shearman MS. Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages. Biochemistry. 2003 Jun 24;42(24):7580-6.</citation>
    <PMID>12809514</PMID>
  </reference>
  <reference>
    <citation>Maillard I, Adler SH, Pear WS. Notch and the immune system. Immunity. 2003 Dec;19(6):781-91. Review.</citation>
    <PMID>14670296</PMID>
  </reference>
  <reference>
    <citation>Stanger BZ, Datar R, Murtaugh LC, Melton DA. Direct regulation of intestinal fate by Notch. Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12443-8. Epub 2005 Aug 17.</citation>
    <PMID>16107537</PMID>
  </reference>
  <reference>
    <citation>Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, Gao H, Higgins MA, May PC, Ryan TP. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem. 2003 Nov 14;278(46):46107-16. Epub 2003 Aug 29.</citation>
    <PMID>12949072</PMID>
  </reference>
  <reference>
    <citation>Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA, Parker EM. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004 Mar 26;279(13):12876-82. Epub 2004 Jan 6.</citation>
    <PMID>14709552</PMID>
  </reference>
  <reference>
    <citation>Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001 Nov 8;414(6860):212-6.</citation>
    <PMID>11700559</PMID>
  </reference>
  <reference>
    <citation>Kukar T, Golde TE. Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage. Curr Top Med Chem. 2008;8(1):47-53.</citation>
    <PMID>18220932</PMID>
  </reference>
  <reference>
    <citation>Peretto I, La Porta E. Gamma-secretase modulation and its promise for Alzheimer's disease: a medicinal chemistry perspective. Curr Top Med Chem. 2008;8(1):38-46. Review.</citation>
    <PMID>18220931</PMID>
  </reference>
  <reference>
    <citation>Peretto I, Radaelli S, Parini C, Zandi M, Raveglia LF, Dondio G, Fontanella L, Misiano P, Bigogno C, Rizzi A, Riccardi B, Biscaioli M, Marchetti S, Puccini P, Catinella S, Rondelli I, Cenacchi V, Bolzoni PT, Caruso P, Villetti G, Facchinetti F, Del Giudice E, Moretto N, Imbimbo BP. Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. J Med Chem. 2005 Sep 8;48(18):5705-20.</citation>
    <PMID>16134939</PMID>
  </reference>
  <reference>
    <citation>Imbimbo BP, Del Giudice E, Colavito D, D'Arrigo A, Dalle Carbonare M, Villetti G, Facchinetti F, Volta R, Pietrini V, Baroc MF, Serneels L, De Strooper B, Leon A. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther. 2007 Dec;323(3):822-30. Epub 2007 Sep 25.</citation>
    <PMID>17895400</PMID>
  </reference>
  <reference>
    <citation>Imbimbo BP, Del Giudice E, Cenacchi V, Volta R, Villetti G, Facchinetti F, Riccardi B, Puccini P, Moretto N, Grassi F, Ottonello S, Leon A. In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents. Pharmacol Res. 2007 Apr;55(4):318-28. Epub 2007 Jan 16.</citation>
    <PMID>17292621</PMID>
  </reference>
  <reference>
    <citation>Imbimbo BP, Hutter-Paier B, Villetti G, Facchinetti F, Cenacchi V, Volta R, Lanzillotta A, Pizzi M, Windisch M. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br J Pharmacol. 2009 Mar;156(6):982-93. doi: 10.1111/j.1476-5381.2008.00097.x.</citation>
    <PMID>19239474</PMID>
  </reference>
  <reference>
    <citation>Sisti R, Nyska A. CHF 5074: 4-week oral toxicity study in rats followed by a 4-week recovery period. RTC Study No. 71470. February 9, 2009.</citation>
  </reference>
  <reference>
    <citation>Grassetti A, Nyska A. CHF 5074. 4 week oral toxicity study in dogs followed by a 4 week recovery period. RTC Study No. 71470. February 4, 2009.</citation>
  </reference>
  <reference>
    <citation>Cinelli S, Oberto G. CHF 5074. Unscheduled DNA Synthesis (UDS) in primary rat hepatocytes after in vivo treatment (autoradiographic methods). RTC Study No. 70270. December 4, 2008.</citation>
  </reference>
  <reference>
    <citation>Ciliutti P, Oberto G. CHF 5074. Micronucleous test in rats. RTC Study No. 70260. November 28, 2008.</citation>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2009</study_first_submitted>
  <study_first_submitted_qc>August 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2009</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

